Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Rebody Health vs Wisp

Rebody Health
Graded #162

Lower grade

vs+7.599999999999994
Wisp
Graded #57

Higher grade

The verdict

Wisp takes it — 75.3/100 to 67.7/100.

Wisp grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWisp +38
46
84
Dose & formulationEven
88
88
Clinical oversightWisp +1
81
82
Labs & monitoringEven
53
53
FulfillmentRebody Health +18
84
66
Contract termsEven
55
55
Rebody Health · left barWisp · right bar

The numbers

MetricRebody HealthWisp
WeighScore67.7/10075.3/100
GradeCC
Scorecard rank#162#57
Semaglutide$200/mo (starting dose, compounded)$225/mo (compounded oral)
Tirzepatide$250/mo (starting dose, compounded)$99/mo (starting dose, brand-name)
Coverage47 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
Rebody Health

Graded #162 · C

Strengths

  • Publishes transparent, dose-based pricing up front on a public pricing page, so you can see costs without signing up
  • Offers compounded semaglutide and tirzepatide as both weekly injections and daily oral 'melt' tablets
  • Also carries brand-name Wegovy and Zepbound for patients who want FDA-approved products
  • Clear plan-term vs dose-tier structure; the refill price is shown before each shipment, plus $50 off the first month
  • Names its operating company (Compound Technologies Inc.) and references LegitScript approval

Where it loses points

  • Individual compounding pharmacies are not named on the marketing site
  • Not available in Massachusetts, Rhode Island, or Vermont
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
  • Dose-scaled pricing means the monthly cost can rise as your prescribed dose increases
Wisp

Graded #57 · C

Strengths

  • Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
  • LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
  • Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary

Where it loses points

  • Sublingual compounded semaglutide hasn't been tested in humans, per Wisp's own page — only the injectables have FDA efficacy data
  • Pharmacy partners not named
  • States served not listed publicly

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard